Key Points
- BioNTech CEO Ugur Sahin sold 34,000 shares at an average price of $96.49, generating approximately $3.28 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan and reduced his holdings by 5.65%.
- Sahin has made several additional sales in September, including 15,000 shares on September 16 and 41,000 shares on September 14, following multiple other transactions earlier in the month.
- BioNTech’s latest quarter showed weaker results, with a loss of $2.53 per share and revenue of $122.31 million, down 59.5% year over year. Analysts nevertheless maintain a “Moderate Buy” consensus, with an average price target of $126.
BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 15,000 shares of the company's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $96.09, for a total transaction of $1,441,350.00. Following the sale, the chief executive officer directly owned 553,209 shares of the company's stock, valued at approximately $53,157,852.81. This trade represents a 2.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total value of $3,280,660.00.
- On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total value of $4,077,450.00.
- On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total value of $4,361,850.00.
- On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total value of $1,974,355.00.
- On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total value of $3,520,080.00.
- On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
- On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00.
- On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total value of $4,628,250.00.
BioNTech Stock Down 0.9%
Shares of NASDAQ:BNTX opened at $95.83 on Thursday. The company has a market capitalization of $24.23 billion, a price-to-earnings ratio of -12.24 and a beta of 1.29. The company has a 50 day moving average of $97.17 and a two-hundred day moving average of $95.00. BioNTech SE Sponsored ADR has a 52-week low of $79.52 and a 52-week high of $124.00. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01.
BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company's revenue for the quarter was down 59.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.60) earnings per share. As a group, analysts forecast that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the stock. Morgan Stanley decreased their price objective on shares of BioNTech from $126.00 to $119.00 and set an "overweight" rating for the company in a research report on Wednesday, July 8th. Canaccord Genuity Group dropped their target price on BioNTech from $142.00 to $136.00 and set a "buy" rating on the stock in a research report on Monday, August 31st. Jefferies Financial Group reiterated a "buy" rating on shares of BioNTech in a research note on Monday, June 1st. Weiss Ratings reissued a "sell (d-)" rating on shares of BioNTech in a report on Monday, July 6th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of BioNTech in a research note on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.
Read Our Latest Report on BNTX
Institutional Trading of BioNTech
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Engineers Gate Manager LP lifted its stake in BioNTech by 17.3% in the second quarter. Engineers Gate Manager LP now owns 12,433 shares of the company's stock valued at $1,157,000 after buying an additional 1,833 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of BioNTech in the second quarter worth $39,000. Nykredit A S acquired a new position in shares of BioNTech during the second quarter valued at $293,000. B. Metzler seel. Sohn & Co. AG raised its stake in shares of BioNTech by 66.7% during the second quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company's stock valued at $1,020,000 after purchasing an additional 4,390 shares in the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of BioNTech during the second quarter valued at about $2,520,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.
BioNTech Company Profile
(
Get Free Report)
BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.
The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.
BioNTech was founded in 2008 and is headquartered in Mainz, Germany.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
